Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMEL1 | Q495T6 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | THRB | P10828 | 1/20 | 0.46 |
| ▸ | MME | P08473 | 3/20 | 0.45 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.44 |
| ▸ | ACE | P12821 | 2/20 | 0.43 |
| ▸ | CTSA | P10619 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.41 |
| ▸ | UTS2R | Q9UKP6 | 3/20 | 0.41 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.40 |
| ▸ | XPO1 | O14980 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10259960 | 0.89 | MMEL1 (0.48) | MMEL1MAPTPOLBTP53THRB | |
| SCHEMBL10259127 | 0.85 | MMEL1 (0.58) | MMEL1MAPTPOLBTP53THRB | |
| SCHEMBL10198457 | 0.83 | MMEL1 (0.66) | MMEL1MMEACE | |
| SCHEMBL10267499 | 0.78 | MME (0.51) | MMEL1MAPTPOLBTP53THRB | |
| SCHEMBL2870271 | 0.77 | MMEL1 (0.71) | MMEL1MMEACE | |
| SCHEMBL6667661 | 0.76 | FFAR1 (0.46) | MMEL1MAPTPOLBMMEFFAR1 | |
| SCHEMBL8552535 | 0.75 | MMEL1 (0.67) | MMEL1MAPTMMEACE | |
| Hydrochloric Acid SCHEMBL7177344 | 0.75 | FFAR1 (0.45) | MMEL1MAPTPOLBMMEFFAR1 | |
| SCHEMBL30671431 | 0.73 | MAPT (0.51) | MMEL1MAPTFFAR1CTSATRPM8 | |
| SCHEMBL12317545 | 0.73 | MME (0.64) | MMEL1MMEACE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120122844-A1 | METHOD OF TREATING CONTRAST-INDUCED NEPHROPATHY | NOVARTIS AG (CH) | 2012-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120122844-A1 | METHOD OF TREATING CONTRAST-INDUCED NEPHROPATHY | REN, SERPINB1, MME | MMEL1 118/4885MAPT 4543/4885POLB 3740/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.